Camelid TB Serology Quarterly Report: 1st January 2021 to 31st March 2021
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number:
Report Period 1st January to 31st March 2021
Issued 21/Apr/2021

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
Serial Test:
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
SER-CHK
Inconclusive Reactor check test – e.g. where private Enferplex test has produced a
2-spot-positive result on 2 consecutive occasions
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be
applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test
interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described
under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test
performance;
Table 1 – High Sensitivity / Parallel test options:
IDEXX /DPP VetTB
ENFER 2-SPOT/DPP VetTB
IDEXX/ENFER 2-SPOT
% Se
74
71
75
95% C.I.
65.4-82.6
62.1-79.9
66.5-83.5
% Sp
96
96.7
97.3
95% C.I.
93.8-98.2
95.8-99.4
95.4-99.1
Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.
Table 2 – High Specificity / Serial test options:
Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.
ENFER 4-SPOT
IDEXX/DPP VetTB
% Se
60
56
95% C.I.
50.4-69.9
46.3-65.7
% Sp
99.66
100
95% C.I.
98.9-100
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.

Quarterly Camelid Serology Report
21 Apr 2021
Table 1a
Country
No.
Samples
Tested
England
271
Wales
25
Non GB
6
Total for Q1
302
Number of Samples tested and Submission Reason  2021 Q1 (January - March)
Table 1b
Submission
Reason
No. Samples
Tested
Parallel
PAR-SUS
5
PAR-TB
126
Parallel
Sum:
131
Serial
SER-CHK
2
SER-COL
7
SER-CONT
143
Serial
Sum:
152
Commercial/Private Testing
SER-MVT
15
SER-RHT
4
Commercial/Private Testing
Sum:
19
Total for Q1
Sum:
302

Quarterly Camelid Serology Report
21 Apr 2021
Table 2a
Country
No.
Samples
Tested
England
271
Wales
25
Non GB
6
Total for Q1
302
Number of Samples tested and Submission Reason 2021 up to end of Q1 (January - March)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
5
PAR-TB
126
Parallel
Sum:
131
Serial
SER-CHK
2
SER-COL
7
SER-CONT
143
Serial
Sum:
152
Commercial/Private Testing
SER-MVT
15
SER-RHT
4
Commercial/Private Testing
Sum:
19
Total for 2021 up to end
of Q1
302

Quarterly Camelid Serology Report
21 Apr 2021
Table 3a
Submissions Received and Test Positivity in 2021 Q1
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-TB
5
118
15
12.7%
Parallel
5
118
15
12.7%
Serial
SER-COL
3
7
0
0
SER-CONT
17
133
4
3.0%
Serial
20
140
4
2.9%
Commercial/Private Testing
SER-MVT
3
9
0
0
SER-RHT
1
4
0
0
Commercial/Private Testing
4
13
0
0
England Total
29
271
19
7.0%
Wales
Parallel
PAR-SUS
1
5
0
0
PAR-TB
2
8
0
0
Parallel
3
13
0
0
Serial
SER-CHK
1
2
0
0
SER-CONT
2
10
0
0
Serial
3
12
0
0
Wales Total
6
25
0
0
Non GB
Commercial/Private Testing
SER-MVT
1
6
0
0
Commercial/Private Testing
1
6
0
0
Non GB Total
1
6
0
0
Totals for Q1
36
302
19
6.3 %
Test Positivity in 2021 Q1 (January - March)

Quarterly Camelid Serology Report
21 Apr 2021
Table 3b
Submissions Received and Test Positivity in 2021 up to the end of Q1
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-TB
5
118
15
12.7%
Parallel
5
118
15
12.7%
Serial
SER-COL
3
7
0
0
SER-CONT
17
133
4
3.0%
Serial
20
140
4
2.9%
Commercial/Private Testing
SER-MVT
3
9
0
0
SER-RHT
1
4
0
0
Commercial/Private Testing
4
13
0
0
England Total
29
271
19
7.0%
Wales
Parallel
PAR-SUS
1
5
0
0
PAR-TB
2
8
0
0
Parallel
3
13
0
0
Serial
SER-CHK
1
2
0
0
SER-CONT
2
10
0
0
Serial
3
12
0
0
Wales Total
6
25
0
0
Non GB
Commercial/Private Testing
SER-MVT
1
6
0
0
Commercial/Private Testing
1
6
0
0
Non GB Total
1
6
0
0
Totals up to
end Q1
36
302
19
6.3 %
Test Positivity in 2021 up to end of Q1 (January - March)

Quarterly Camelid Serology Report
21 Apr 2021
Submissions Received in 2021 up to end of Q1
Analysis
Analysis Description
Q1
No.
samples
tested
Totals up to end Q1
TC0503
Camelid TB Enferplex - 2
Spot
114
114
TC0603
Camelid TB Enferplex - 4
Spot
118
118
TC0611
Chembio DPP VetTB lateral
flow rapid antibody test
81
81
TC0867
Camelid TB Antibody
ELISA
173
173
Table 4: Number of samples Tested by Test Code